• Founded: 2013
  • Location: Pittsburgh, PA
  • Employee range: 11 - 50
  • Clinical stage: Clin2
  • Therapy area: Prosthetic joint infection (ODD)
  • Drug types: INF, BON, LNG, GEN, RAR, ONC
  • Lead product: PLG0206
  • Product link:
  • Funding: $35.4M B Dec 2020
  • Investors: Presight Capital, Founders Fund, Peter Thiel

job board

Short description:

Peptide Therapeutics

Drug notes:

Also Clin0 orthopedic condition; PLG0301 Clin0 cystic fibrosis infection & inflammation; PLGA1002 RD rare genetic disease; PLGA1003 RD oncology; PLGA1004 RD oncology

Long description:

Peptilogics is combining machine learning with untapped potential in peptide biology to advance novel drugs. Using their AI platform, Nautilus, Petilogics is performing in silico predictive peptide design to access new functional chemical space with desired binding, selectivity and safety properties for different targets. Nautilus is built upon public and proprietary data from chemistry, biology and pharmacology and ranks generated peptide sequences following multiparameter screening. Peptilogics’ approach works for linear, cyclic and nonstard amino acid peptides and is extensible to all disease areas. Peptilogics’ lead candidate, PLG0206, is an antibiotic peptide for the treatment of periprosthetic joint infection and is currently being investigated in patients in a clinical trial.


General Application
Pittsburgh, PA|100+ days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy